The immunoglobulin E (IgE) blocking agent omalizumab is a biologic therapeutic agent widely used as an adjunctive treatment in patients with persistent moderate-to-severe asthma, and markers of type 2 inflammation are used as predictors of anti-IgE treatment response [8]. The gene discussed is IGHE; the disease is asthma.